Mouse models incorporating alterations in the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapetutic agents. Exp Lung Res 2005;31(1):117-33
Date
03/16/2005Pubmed ID
15765922DOI
10.1080/01902140490495499Scopus ID
2-s2.0-11144228245 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
This review is primarily a follow up to an initial review on this subject that the authors published 4 years ago [Lubet et al., Exp Lung Res. 2000; 581-593]. The present review gives a brief discussion of certain background points and rationale for development of these specific models, which had been presented in greater detail in the earlier article. In that initial article the authors identified the potential use of mutant mice in screening for carcinogens as well as preventive or therapeutic agents, discussed the relevance of the dominant-negative P53 mutation, as contrasted with knockout P53 mice, and briefly discussed the pros and cons of mice with a germline mutation in tumor suppressor genes in developing mouse models. The primary objective of the present review is to describe more recent studies using mice the dominant-negative P53 mutation as well as to introduce studies with mice with a heterozygous knockout of the P16/Ink4A ARF locus.
Author List
Lubet R, Wang Y, Zhang Z, You MMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAnimals
Anticarcinogenic Agents
Carcinogenicity Tests
Chemoprevention
Disease Models, Animal
Drug Screening Assays, Antitumor
Genes, p16
Genes, p53
Lung Neoplasms
Mice
Mice, Mutant Strains
Mutation
